H. Res. 345 is a sense‑of‑the‑House resolution that urges recognition of April 2025 as a month dedicated to Parkinson’s awareness.
The text assembles public‑health findings about prevalence, projected growth, symptoms, and costs, and it uses those findings to call for more research, community support, and recognition of people living with the disease and their caregivers.
The resolution carries no statutory or budgetary authority: it neither creates programs nor appropriates funds. Its practical effect is symbolic—raising congressional attention and giving advocates a vehicle for outreach—but that symbolism can influence agency messaging, grant makers, and public fundraising efforts even though the measure does not mandate action.
At a Glance
What It Does
The resolution recites findings about Parkinson’s disease and expresses the House’s support for designating April 2025 as an awareness month; it also affirms support for research, recognizes clinical‑trial participants, and commends organizations and volunteers. It is a non‑binding statement of congressional sentiment rather than a law that changes programs or spending.
Who It Affects
Directly affected stakeholders are people with Parkinson’s disease and their families, patient advocacy groups, clinical‑trial networks, researchers, and health‑care providers who run outreach or education programs. Congressional staff and federal agencies may be asked to participate in awareness events or briefings.
Why It Matters
Though symbolic, the resolution signals congressional attention to Parkinson’s disease and compiles quantitative findings that advocates can cite. That spotlight can boost recruitment for trials, support fundraising, influence agency communications, and shape the public narrative around funding priorities.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
H. Res. 345 is a short, text‑only House resolution that compiles a set of factual statements about Parkinson’s disease and then records the chamber’s support for an awareness month and related goals.
The bill opens with 'whereas' clauses summarizing disease prevalence, annual diagnosis rates, clinical manifestations, and projected economic burden; those findings provide the rationale for the chamber’s expressions of support.
The operative clauses record five discrete actions: endorsing the awareness month; endorsing the goals and ideals associated with that observance; restating support for continued research aimed at better treatments and a cure; acknowledging people who enroll in clinical trials; and commending the work of organizations, volunteers, and researchers. None of those clauses creates new legal obligations or spending; they are declarative and aimed at recognition and encouragement.From an implementation standpoint, the resolution puts no compliance requirements on private parties and no new administrative mandate on agencies.
Its practical effects will be mediated through soft channels—congressional press releases, committee events, hearings, and constituent outreach—that amplify the research and caregiving messages. Because the text references specific epidemiological and cost estimates, it also furnishes a compact set of talking points that stakeholders can reuse in grant applications, advocacy letters, or public education campaigns.Procedurally, the resolution was introduced in the House and referred to the Committee on Energy and Commerce.
If the House adopts it, the adoption itself is the end result: there is no implementing regulation or appropriation to follow. The primary operational consequence is reputational and communicative—who uses the resolution as cover for events, funding appeals, or recruitment drives will determine how far its effects travel.
The Five Things You Need to Know
H. Res. 345 was introduced April 24, 2025, by Rep. Wesley Bell (D) with Rep. Gus Bilirakis (R) and referred to the House Committee on Energy and Commerce.
The bill cites that Parkinson’s affects more than 1,000,000 Americans and reports nearly 90,000 new U.S. diagnoses each year.
It incorporates a projection that U.S. cases will nearly double by 2037 and estimates an annual cost to the United States of at least $80 billion by that year.
The resolution explicitly recognizes individuals who participate in clinical trials and calls for continued research, but it does not authorize funding or change existing research programs.
This is a sense‑of‑the‑House measure only: adoption would be symbolic and communicative, not legally binding or budgetary.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Findings about Parkinson’s prevalence, causes, symptoms, and costs
The preamble gathers epidemiological claims and projections—case counts (>1 million), annual diagnoses (~90,000), disease ranking (15th leading cause of death per CDC), suspected etiologies, and a projected near doubling of cases with a projected $80 billion annual cost by 2037. Those recitals do two things in practice: they provide justification for the resolution’s calls to action and they supply easily cited statistics that advocates and committees may reuse in hearings or press materials.
Endorsement of an awareness month
This clause records the House’s support for designating April 2025 as a month for Parkinson’s awareness. Mechanically, that endorsement is ceremonial—if the House adopts the resolution, it becomes an official expression of congressional sentiment but creates no statutory obligation or new federal program.
Support for goals and ideals linked to awareness
This clause is aspirational, aligning the chamber with educational and community objectives commonly associated with health observances: increasing public understanding, reducing stigma, and promoting early diagnosis and care. The practical implication is tactical: stakeholders may leverage the House’s stated support to coordinate campaigns or secure visibility in federal briefings.
Affirmation of research priorities and recognition of trial participants
These clauses reiterate congressional support for ongoing research and specifically acknowledge volunteers who enroll in clinical trials. They do not change research funding authorities, but the explicit recognition of trial participants may aid recruitment messaging and emphasize the research community’s role in advancing treatments.
Commendation of organizations and volunteers
The final clause commends nonprofits, volunteers, and researchers. That public commendation functions as political cover for organizations to publicize their work, increases legitimacy for volunteer efforts, and signals to donors and partners that Congress is attuned to these activities—again without attaching funding or regulatory consequences.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- People living with Parkinson’s disease and their families — the resolution increases public visibility and can reduce stigma while supplying shareable statistics and narratives that advocates can use for outreach.
- Patient advocacy and nonprofit organizations — they gain a congressional imprimatur that can boost fundraising appeals, event attendance, and media placements.
- Clinical‑trial sponsors and research centers — the explicit recognition of trial volunteers helps recruitment messaging and may modestly ease enrollment challenges.
- Researchers and academic centers — the resolution highlights research priorities and compiles talking points that can be cited in testimony and grant applications.
- Healthcare providers and public‑health communicators — the House statement provides a hook for education campaigns, screenings, and community events during April 2025.
Who Bears the Cost
- Congressional and committee staff — minimal administrative and communications time to process, debate, and publicize the resolution; these are incremental operational costs charged to existing staff resources.
- Federal agencies asked to participate in events or briefings — agencies may allocate staff time to coordinate outreach or produce educational materials without additional appropriations.
- Advocacy organizations — while benefitting from increased visibility, groups may reallocate limited resources to respond to new opportunities (events, media requests, campaign materials) rather than to other priorities.
- Private health systems and clinical sites — if they take on outreach or trial‑recruitment efforts tied to the awareness month, they may incur costs for marketing, staff time, and event logistics.
Key Issues
The Core Tension
The central dilemma is symbolic recognition versus substantive change: the resolution effectively raises the profile of Parkinson’s disease and may aid outreach, but it stops short of directing resources; lawmakers and stakeholders must decide whether a declaration is sufficient or whether it should be the prelude to appropriation, regulatory change, or program expansion.
The resolution’s primary limitation is its symbolic form. It assembles facts and issues exhortations but does not create new authority or funding streams; therefore, the translation from awareness to concrete services or research dollars depends entirely on follow‑on actions by appropriators, agencies, and private funders.
That gap creates an implementation ambiguity: policymakers and advocates may cite the resolution to press for resources, but the measure itself imposes no obligation on executive branch agencies or the appropriations process.
Another tension arises from reliance on projections and aggregate statistics. The bill uses headline numbers and a forecasted economic cost to build urgency, but those figures carry methodological uncertainty and may be contested in budget or research debates.
Finally, while awareness months can concentrate attention, they can also fragment advocacy calendars (multiple competing observances) and generate short‑term spikes in interest that fade unless matched by sustained policy or funding commitments.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.